Laboratoire de Chimie et Physique-Approche Multi échelle des Milieux Complexes (LCP-A2MC), Institut Jean Barriol, Université de Lorraine, Metz, France.
Anal Biochem. 2012 Nov 1;430(1):83-91. doi: 10.1016/j.ab.2012.08.006. Epub 2012 Aug 16.
The cell division cycle 25 phosphatases (CDC25s) are key regulators of the physiological cell cycle progression. Their overexpression has been reported in a significant number of cancers, and their inhibition appears to be an interesting strategy for treatments. We propose here a rapid screening test allowing the detection of reversible and irreversible CDC25A and -C inhibitors. The test is based on the incubation of the candidate molecules with the human CDC25 proteins followed by an ultrafiltration step. The retentate is then directly analyzed by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOFMS) to detect reversible inhibitors or submitted to peptide mass fingerprint (PMF) analysis to reveal irreversible inhibitors covalently bound to the protein active site. After its validation, the protocol is applied to the detection of a novel candidate inhibitor of CDC25s named SV37. The screening procedure, as well as the preliminary biological results, demonstrates that this compound behaves as a reversible inhibitor.
细胞周期蛋白 25 磷酸酶(CDC25s)是生理细胞周期进程的关键调节剂。大量研究报告表明,它们在许多癌症中过度表达,抑制它们的活性似乎是一种很有前途的治疗策略。在这里,我们提出了一种快速筛选试验,可以检测可逆和不可逆的 CDC25A 和 -C 抑制剂。该试验基于候选分子与人类 CDC25 蛋白孵育,然后进行超滤步骤。然后,将保留物直接通过基质辅助激光解吸/电离飞行时间质谱(MALDI-TOFMS)分析以检测可逆抑制剂,或进行肽质量指纹图谱(PMF)分析以揭示与蛋白活性位点共价结合的不可逆抑制剂。在验证后,该方案应用于检测一种名为 SV37 的新型 CDC25 候选抑制剂。筛选程序以及初步的生物学结果表明,该化合物表现为可逆抑制剂。